Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Finished Goods (2025)

BridgeBio Pharma's Finished Goods history spans 1 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Finished Goods changed N/A year-over-year to $6.5 million; the TTM value through Dec 2025 reached $6.5 million, changed N/A, while the annual FY2025 figure was $6.5 million, N/A changed from the prior year.
  • Finished Goods for Q4 2025 was $6.5 million at BridgeBio Pharma, up from $5.0 million in the prior quarter.
  • Across five years, Finished Goods topped out at $6.5 million in Q4 2025 and bottomed at $2.6 million in Q1 2025.